Portal de Periódicos da CAPES

Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County

2017; SAGE Publishing; Volume: 29; Issue: 6 Linguagem: Inglês

10.1177/0956462417743158

1758-1052

Matthew R. Beymer, Ryan Kofron, Chi‐Hong Tseng, Robert Bolan, Risa Flynn, Jennifer M Sayles, Mario Pérez, Wilbert Jordan, Raphael J. Landovitz,

HIV/AIDS drug development and treatment

Post-exposure prophylaxis (PEP) is a promising but under-utilized strategy for HIV prevention in high-risk populations. Between March 2010 and June 2011, two community-based clinics in Los Angeles County provided PEP in a pilot program to 267 unique individuals. Courses were primarily dispensed to men who have sex with men (84%) and consisted overwhelmingly of a three-drug antiretroviral therapy regimen containing two nucleoside reverse transcriptase inhibitors and either an integrase inhibitor (raltegravir) or a boosted protease inhibitor (lopinavir/ritonavir). Approximately 64% of all PEP courses were followed for at least 12 weeks, and seven individuals seroconverted. Of the seven seroconversions, six had subsequent re-exposure. The low rate of PEP failure calls for expanded funding for PEP in other jurisdictions.